奥沙利铂联合吉西他滨治疗晚期原发性肝癌疗效观察

目的:评价奥沙利铂联合吉西他滨(GEMOX)方案治疗晚期原发性肝癌(PLC)的疗效与安全性。方法:30例接受GEMOX方案治疗的晚期PLC患者,分别以实体瘤疗效评定标准1.1版和美国国立癌症研究所通用不良事件术语标准4.0版评价其疗效和不良反应。结果:30例患者均可评价近期疗效,其中获得部分缓解2例,疾病稳定22例,疾病进展6例;客观有效率为6.7%,疾病控制率为80.0%。患者的中位至肿瘤进展时间为3.9个月,中位生存时间为9.4个月。25例患者临床症状和Karnofsky功能状态评分均有一定程度改善。不良反应主要为骨髓抑制、脱发、轻中度消化道反应和轻度周围神经毒性,经治疗后均恢复正常。结论:GEMOX方案治疗晚期PLC具有较好的临床疗效,不良反应可以耐受。

Gemcitabine plus oxaliplatin for treatment of advanced primary liver cancer

Objective:To analyze the efficacy and safety of oxaliplatin combined with gemcitabine( GEMOX) for treatment of patients with advanced primary liver cancer( PLC) . Methods:Thirty patients with advanced PLC received the systemic chemotherapy of GEMOX regimen. The efficacy and toxicity were evaluated every 2 cycles by the criteria of Response Evaluation Criteria in Solid Tumors,version 1. 1 and the National cancer institute-common terminology criteria adverse events, version 4. 0. Results:All the 30 patients were evaluable for short-term efficacy. Partial response was observed in 2 cases,stability in 22 cases and progression in 6 cases. The objective response rate was 6. 7% and the disease control rate was 80. 0%. The median time to progression and the overall survival time were 3. 9 and 9. 4 months, respectively. Clinical symptoms and Karnofsky scores were improved in 25 cases. The main adverse effects were hematologic toxicity,alopecia,mild to moderate gastrointestinal reaction and mild periphery neurotoxicity,which returned to normal after treatment. Conclusions:GEMOX regimen is effective for treatment of advanced PLC with tolerable adverse effects.